Chemo-immunotherapy Not Better Than Chemotherapy Alone for ... Cancer Consultants, ID - Nov 17, 2008 Immunotherapy agents include interferon-alfa (INF-alfa) and interleukin-2 (IL-2). However, most therapy is palliative, thus tolerability of treatment is a ...
ZymoGenetics Inc Q3 2008 Earnings Call Transcript Seeking Alpha, NY - Nov 19, 2008 We will also update you on the progress of the Interleukin 21 and the Atacicept programs and after that I will update you on the RECOTHROM sales. ...ZGEN
Recent News and Articles on the Keywords: experimental therapy + 2,070 + can Related to the article below (Last Update: 8/7/2008)
Cancer test patient -- with a wet nose Minneapolis Star Tribune, MN - Batman is taking part in an experimental therapy that could help people, too. A Minneapolis dog is the first to try an experimental treatment that could ...
Pet Dog Undergoing Experimental Cancer Treatment Dog Flu Diet and Diseases, Canada - On Tuesday this furry family member of Anna and Eric Baker underwent an experimental therapy at the University of Minnesota that they hope will cure his ...
New therapy 'better for prostate cancer' Sydney Morning Herald, Australia - Jul 28, 2008 Scientists have discovered an experimental therapy for advanced prostate cancer that is more effective and has fewer side effects than current treatment. ...
FDA Safety Changes: Depakote, Depakote ER, Antibiotics Medscape (subscription) - Some in vitro studies also suggest that valproate therapy may stimulate HIV and cytomegalovirus viral replication in certain experimental conditions. ...
Can Medication Replace Talk Therapy? eFluxMedia - Aug 5, 2008 The procedure include a range of techniques based on experimental relationship building, dialogue, communication and behavior change designed to improve the ...
GTx losses continue but drug hopes high Memphis Commercial Appeal, TN - Aug 5, 2008 ... types of hormone treatments, not just androgen deprivation therapy, Steiner said. GTx also provided updates on several other experimental drug programs. ...GTXI
Heal Yourself With Stem Cells WFtv.com, FL - ADULT STEM CELL THERAPY: Some research shows that adult stem cells can be used to strengthen damaged organs like hearts and livers. Experimental treatments ...
?We plan to bring out innovative tailor-made cells for diseases? Hindu Business Line, India - Jul 27, 2008 ?The stem cells used in our experimental therapy are Mesenchymal stem cells, which are derived from your own bone marrow. These are multi-potent stem cells ...
Factors Influencing Infarct Size Following Experimental Coronary Artery Occlusions - PR MAROKO, JK KJEKSHUS, BE SOBEL, TAN WATANABE, JW … - Circulation, 1971 - Am Heart Assoc ... Factors Influencing Infarct Size Following Experimental Coronary Artery ... assessing
the efficacy of reperfusion therapy J. Am. ... April 1, 1995; 91(7): 2058 - 2070. ...
Defining the success of cardiac gene therapy: how can nuclear imaging contribute? - N Avril, FM Bengel - European Journal of Nuclear Medicine and Molecular Imaging, 2003 - Springer ... vascular function and enabled targeted therapy of diseases ... rejection [1, 2]. In the experimental setting, assessment ... using reporter genes that can be detected ...
Interleukin-12 can safely be administered with Interferon as an experimental therapy for some cancers
A study has shown that the immune-stimulating hormone known as Interleukin-12 ( IL-12 ) can safely be administered with Interferon, another immune-system protein, as an experimental therapy for some cancers.
Normally, Interferon is used alone to stimulate the immune system to attack certain cancers. This strategy, a form of immunotherapy, is sometimes used to treat melanoma, advanced kidney cancer and other tumors that respond poorly to chemotherapy or radiation therapy. But Interferon can have serious side effects that limit its use.
Surprisingly, the two drugs used in sequence caused no serious side effects in patients.
" Interferon can be quite toxic when used alone," says principal investigator William E. Carson, III, at the Ohio State University Comprehensive Cancer Center.
" We were initially concerned that the addition of IL-12 might increase that toxicity. Instead, we found that the two drugs can be used together without additional side effects."
The findings in the Journal of Clinical Oncology.
They suggest that IL-12 primes white blood cells such that a lower dose of Interferon will stimulate the same level of immune activity as a higher dose of Interferon when used alone.
The results come from a phase-I clinical trial, which marks the first time a treatment is tried in human subjects.
The trial, conducted by Carson and a team of colleagues, involved 49 patients ages 23 to 84 with different types of advanced cancer, including cancers of the colon, lung, kidney and bladder and melanoma.
On the first day of treatment, patients were given IL-12, initially by injection and then intravenously. That was followed by injections of Interferon over the next five days.
On average, patients received five such cycles over the course of the study.
The drug combination not only proved to be safe – which was the purpose of the study – but the researchers found that it stopped disease progression in five of the patients for at least six months.
" Our findings were encouraging," Carson says. " They indicate that we can safely administer IL-12 in combination with Interferon, that it enhances the action of Interferon in some patients with advanced cancer, and that it can be an effective way to stimulate the immune system."
Based on the study's results, and the results of earlier animal studies led by the research group, Carson and his colleagues are conducting a multicenter phase II clinical trial of the two drugs in people with melanoma.
Phase-II trials are the first step in determining the effectiveness of new therapy against a specific disease.
" We believe that use of the two drugs together will give us more bang for the buck," says first author Gregory B. Lesinski, in the Human Cancer Genetics Program.
" We hope that the IL-12 will allow us to use lower doses of Interferon in patients, which should result in fewer side effects and potentially a longer use of interferon, giving the immune system more time to fight the tumor."
